We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

38 hedge funds and large institutions have $22.2M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

6% more funds holding

Funds holding: 36 → 38 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

20% less capital invested

Capital invested by funds: $27.8M → $22.2M (-$5.59M)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
38
Holders Change
+2
Holders Change %
+5.56%
% of All Funds
0.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
5
Reduced
10
Closed
3
Calls
$83K
Puts
–
Net Calls
+$83K
Net Calls Change
-$22K

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$123K
2
Millennium Management
Millennium Management
New York
+$69.7K
3
State Street
State Street
Massachusetts
+$48.4K
4
Prudential Financial
Prudential Financial
New Jersey
+$36.2K
5
TC
Titleist Capital
Texas
+$21.8K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$212K
2
Two Sigma Investments
Two Sigma Investments
New York
-$93.5K
3
Morgan Stanley
Morgan Stanley
New York
-$77K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$15.9K
5
AWS
Atria Wealth Solutions
New York
-$12.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Athyrium Capital Management
New York
$11.1M – – –
RA
2
Rovida Advisors
Florida
$4.02M – – –
ACH
3
ArrowMark Colorado Holdings
Colorado
$2.21M – – –
Morgan Stanley
4
Morgan Stanley
New York
$1.66M -$77K -53,164 -4%
Renaissance Technologies
5
Renaissance Technologies
New York
$1.14M -$212K -146,216 -15%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$357K +$14K +9,692 +4%
Vanguard Group
7
Vanguard Group
Pennsylvania
$302K +$21K +14,493 +7%
BlackRock
8
BlackRock
New York
$282K -$7.25K -5,009 -2%
MWM
9
Marietta Wealth Management
Georgia
$163K – – –
TC
10
Titleist Capital
Texas
$161K +$21.8K +15,033 +15%
ACM
11
AIGH Capital Management
Maryland
$116K +$123K +84,993 New
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$99K – – –
State Street
13
State Street
Massachusetts
$98K +$48.4K +33,403 +86%
Northern Trust
14
Northern Trust
Illinois
$97K -$5.59K -3,860 -5%
Millennium Management
15
Millennium Management
New York
$65K +$69.7K +48,125 New
IA
16
Insight Advisors
Pennsylvania
$59K – – –
Charles Schwab
17
Charles Schwab
California
$45K – – –
AWS
18
Atria Wealth Solutions
New York
$37K -$12.2K -8,400 -24%
Prudential Financial
19
Prudential Financial
New Jersey
$34K +$36.2K +25,000 New
Wells Fargo
20
Wells Fargo
California
$32K +$33 +23 +0.1%
Two Sigma Investments
21
Two Sigma Investments
New York
$30K -$93.5K -64,524 -74%
EGM
22
Engineers Gate Manager
New York
$30K -$7.7K -5,318 -20%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$24K -$579 -400 -2%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$16K – – –
WJWM
25
Williams Jones Wealth Management
New York
$14K – – –
1
2

RVLP Hedge Fund Activity: Q2 2022 in Review

38 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2022, worth a combined $22.2M — down 20% from $27.8M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new RVLP positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 10 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $123K. The largest seller was Renaissance Technologies, cutting an estimated $212K.

  • 38 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2022, up from 36 in Q1 2022.
  • Funds reported $22.2M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2022, down 20% quarter-over-quarter.
  • 6 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2022 and 3 closed out, a net change of +3 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2022 was AIGH Capital Management, an estimated $123K added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2022 was Renaissance Technologies, an estimated $212K sold.

Based on aggregated 13F filings for Q2 2022.